REPLY
19.9.2023 09:31:27 CEST | Business Wire | Press release
Reply, a global systems integrator and consulting firm and Oracle Cloud Managed Service Provider, has received 4 Oracle Partner awards in recognition of its capabilities to deliver pioneering solutions, drive business value and customers success. The EMEA Cluster Partner Awards, announced at the Oracle EMEA Partner Appreciation Reception during Oracle CloudWorld in Las Vegas, have been awarded to the Reply companies specialized on Oracle technologies; Healthy Reply, Nimbus Reply and Red Reply.
The awards celebrate partners that foster innovation, accelerate business growth and create value to enable success for customers through technology integration and services built on Oracle Cloud Application, Oracle Cloud Infrastructure and Oracle Database technology. The Reply companies, focused on Oracle Cloud Infrastructure solutions and experts in end-to-end Oracle solutions, received the following EMEA Cluster Partner Awards:
- 2023 Customer Success Partner of Year – Europe South Tech / Cloud has been given to Nimbus Reply for the high customer satisfaction they have earned by empowering customers with innovative multi-cloud solutions. These resulted in a reduction of operational costs, an increase in application performance and improvements in system scalability, all while considering critical regulatory requirements.
- 2023 Customer Success Partner of Year – Europe North & East Tech / Cloud has been awarded to Red Reply for their capabilities to increase value to their end customers by streamlining solution implementation and management, improving human capital efficiency, reducing costs, minimizing technical debt, and achieving a measurable return on investment.
- 2023 Business Impact Partner of Year – Europe South Apps / SaaS has been assigned to Healthy Reply for developing exceptional solutions based on Oracle SaaS for the healthcare industry. The solutions developed allow to expedite projects and maximise the benefits of Cloud releases resulting invaluable for clients in managing specific processes and integrating with healthcare national systems.
- 2023 Innovation Partner of Year – Europe North & East Tech / Cloud has been granted to Red Reply for their capabilities to create pioneering solutions that empower customers and support these meeting their business goals and challenges. Red Reply have developed a solution that enables companies to seamlessly migrate their Legacy applications to the Cloud quickly. This rapid migration not only results in immediate cost savings but also enhances the company’s operational efficiency. Additionally, the system allows the transformation of Legacy Applications into Cloud-based Software-as-a-Service (SaaS) through a fully managed service, thus eliminating the need for extensive in-house development resources.
Filippo Rizzante, CTO at Reply, said, “We are delighted to have won these awards that reflect our continuous commitment in delivering cutting-edge Oracle solutions. Our ongoing investments in innovation and research & development, together with the expertise and capabilities of our companies dedicated to Oracle technologies allow us to support our customers better and to get the most from Oracle solutions.”
Reply, Oracle partner since 1997, with its companies dedicated to Oracle technologies, is best in class in Oracle Cloud Computing. With over 1500 certifications Oracle, Reply owns and manages one of the main European centers of competence. Reply is able to combine the full coverage of the entire supply chain, has experience in Oracle application suites, in Oracle technologies and in the main Oracle vertical solutions for the industry.
More information about Reply and Oracle partnership here.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Healthy Reply
Healthy Reply is the Reply Group company specialising in telemedicine, telemonitoring and the continuity of social welfare. Healthy Reply collaborates with public and private healthcare institutions and bodies, clinics and hospitals, social and healthcare facilities, insurance companies and banks, convention centres and enterprises, to design customised services that can guarantee continuous care and assistance. Healthy Reply has established strong competencies in Oracle ERPM Cloud solutions and continue to invest in expanding its offerings across all Oracle SaaS solutions.
Nimbus Reply
Nimbus Reply is the Reply Group company specialising in the delivery of Multi-Cloud solutions for the Health and Public Sector market. Composed of specialists with expertise in several Cloud Service Providers, Nimbus Reply promotes the adoption and evolution of the Cloud paradigm in the Public Sector, supporting end-to-end customers in the Journey to Multi-Cloud, in a Cloud Continuum perspective.
Red Reply
Red Reply is the Reply Group company specialising in Oracle Cloud Infrastructure with a focus on IaaS and PaaS solutions and offers Cloud Strategy and Migration, Application Development, Cloud / Application Management and Operations services. Red Reply is an expert in end-to-end Oracle solutions and one of first Oracle Cloud Managed Service Providers (MSP) in Europe. www.red.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919738958/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom